Pharmaceuticals

Minghui Pharmaceutical Inc. Announces First Patient Dosing in Phase 1 Clinical Studies of Both the Antibody-Drug Conjugate Programs Targeting TROP-2 or B7-H3 Respectively, for Treatment of Advanced or Metastatic Solid Tumors

SHANGHAI and HANGZHOU, China and WILMINGTON, Del., June 20, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, announced today that the first dosing has been completed in two phase 1 clinical studies evaluating MHB036C and MHB088C. The studies a...

2023-06-20 18:30 5543

Curocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023

* 84% ORR (32 of 38 patients) and 71% CR (27 of 38 patients) documented after 2 million cells/kg dose anbal-cel treatment to patients in relapsed/refractory large B-cell lymphoma * Durable complete response was measured-68% at 1 month, 61% at 3 months, and 60% at 6 months respectively. DAEJEO...

2023-06-20 08:01 1609

The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer

NANJING, China, June 16, 2023 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the phase I/II clinical trial application for LBL-033, an anti-MUC16/CD3 bispecific antibody, for the treatment of ovarian cancer and other m...

2023-06-16 22:01 2831

Mabwell Publishes the Preclinical Study Results on Its Nectin-4 Targeting ADC in A Well-known AACR Journal

SHANGHAI, June 15, 2023 /PRNewswire/ -- Recently, the preclinical study results of 9MW2821, the first domestically developed Nectin-4-targeting ADC by Mabwell, were published in the renowned journal "Molecular Cancer Therapeutics" under the American Association for Cancer Research (AACR). The pap...

2023-06-15 21:00 2595

China Jo-Jo Drugstores Reports Fiscal Year 2023 Financial Results

HANGZHOU, China, June 15, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced its finan...

2023-06-15 21:00 5211

Mabwell Announces the U.S. FDA approval of 9MW3811 for IND

SHANGHAI, June 15, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the entire value chain of the pharmaceutical industry, announced the clinical trial application of its self-developed 9MW3811 injection for idiopathic pulmonary fibrosis has been approved by ...

2023-06-15 21:00 2594

Addentax Group Corp. in Advanced Talks to Acquire Partial Stake in RMB 6 Billion-Valued Recombinant Protein Drugs and Antibody Drugs Bio-pharmaceutical Company, Shanghai Bao Pharmaceutical Company Limited

SHENZHEN, China, June 15, 2023 /PRNewswire/ -- Addentax Group Corp. ("Addentax" or the "Company") (Nasdaq: ATXG), an integrated service provider focusing on garment manufacturing, logistics services, property management and subleasing, and epidemic prevention supplies, today announced that it is ...

2023-06-15 20:00 4682

FDA Approved Utidelone Injectable (UTD1) Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer

SAN FRANCISCO, June 15, 2023 /PRNewswire/ -- Biostar Pharma, Inc. (hereinafter referred to as "Biostar"), the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of innovative...

2023-06-15 19:31 2487

Springer Nature to Join Seegene's OneSystem™ Business as Strategic Partner

* Seegene announces strategic partnership with Springer Nature to expand OneSystem™ Business * Seegene and Springer Nature to jointly launch global assay development project * Springer Nature expresses active support for Seegene's vision to promote participation across global scientific com...

2023-06-15 19:00 2196

Telix Briefing: Innovation in Urology to Feature Key Opinion Leaders in Prostate and Kidney Cancer

June 21, 2023, at The Yale Club, New York City  Featured speakers and Key Opinion Leaders include: Dr Christian Behrenbruch, DrColin Hayward, Kevin Richardson, Dr Brian Shuch and Dr Scott Tagawa Topics include Telix's urologic pipeline, development of novel therapeutics, imaging agents and techn...

2023-06-15 19:00 2455

111, Inc. Announces First Quarter 2023 Unaudited Financial Results

SHANGHAI, June 15, 2023 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the first quart...

2023-06-15 13:22 4099

Metagen Therapeutics Completes Series A Financing Raising a Total of 1.7 Billion Yen

TSURUOKA, Japan, June 15, 2023 /PRNewswire/ -- Metagen Therapeutics (President & CEO:Taku Nakahara), a company focusing on drug discovery and development based on intestinal microbiome-based therapeutics for various diseases, has completed its Series A funding in 2 rounds, raising a total of1.7 b...

2023-06-15 13:00 3240

MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China

SHANGHAI and HANGZHOU, China, June 14, 2023 /PRNewswire/ -- MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, announced today that the first healthy volunteer dosed in the Phase 1 study of their oral small-molecule glucagon-like peptide 1 receptor agonist (...

2023-06-14 20:00 2450

Seegene and Werfen Partner to Collaborate on OneSystem™ Business to Develop Syndromic qPCR Assays

SEOUL, South Korea, June 14, 2023 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company which provides a total solution for PCR molecular diagnostics, announced an agreement with Werfen, a worldwide leader in Specialized Diagnostics, to advance discussions on the expansion of it...

2023-06-14 19:00 2631

Gencurix Obtains Approval for Companion Diagnostic of Digital PCR-based EGFR Mutation Test

SEOUL, South Korea, June 13, 2023 /PRNewswire/ -- Gencurix , a leading cancer molecular diagnostics company, has obtained approval from the Korean Ministry of Food and Drug Safety for its Droplex EGFR Mutation Test v2. This product is a companion diagnosti...

2023-06-14 09:00 2888

Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)--The World's First Oral Epothilone Anti-Cancer Drug

SAN FRANCISCO, June 12, 2023 /PRNewswire/ -- Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of innovative oncology drugs, is pleased to announce...

2023-06-12 21:30 2694

Fresh2 Group Ltd. Regains Compliance with Nasdaq Listing Requirements

NEW YORK, June 12, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: FRES), a company with operations inthe United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerc...

2023-06-12 21:00 3827

HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson's Disease

* HanAll Biopharma and Daewoong Pharmaceutical have co-invested in Vincere Biosciences. * These mission-aligned companies are collaborating to develop small-molecule therapies for Parkinson's patients, benefiting from their combined expertise in clinical development and disease biology. * T...

2023-06-12 19:00 3436

Sanyou Milestones | Super Trillion Common Light Chain Antibody Discovery Platform Launched

SHANGHAI, June 11, 2023 /PRNewswire/ -- On June 12th, 2023 local time, Sanyou Biopharmaceuticals Co., Ltd. officially announced the launch of "Sanyou Super Trillion Common Light Chain Antibody Discovery Platform" (the "platform").   As one of the nine trillion antibody discovery platforms of San...

2023-06-12 08:00 2209

ACROBiosystems Aneuro Partners with Diagnostic Biochips to Accelerate Neuroscience Drug Discovery

NEWARK, Del., June 9, 2023 /PRNewswire/ -- ACROBiosystems, through ACRO Certify and under its Aneuro brand, recently announced the launch ofin vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips. Together, two companies are committed to a collaborative effort to ac...

2023-06-09 19:43 4456
1 ... 86878889909192 ... 153

Week's Top Stories